UAE Regulator Emirates Drug Establishment Signs Viatris MOU to Localise Pharmaceutical Manufacturing
UAE's Emirates Drug Establishment signs MOU with Viatris to localise pharmaceutical manufacturing via Adcan Pharma, boosting local production, talent and s
Research Desk
A cooperation agreement between Viatris and Adcan Pharma targets the localization of pharmaceutical manufacturing for a selected group of the global company's products in the United Arab Emirates.
Viatris Agrees to Produce Selected Products Locally Through Adcan Pharma
The deal, signed by Dr. Tamer El Salab on behalf of Viatris and Dr. Foukion Sinis, Chief Executive Officer of Adcan Pharma, is intended to strengthen the integration between international expertise and national capabilities, support the transfer of knowledge and technologies, and expand the local production base.
Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, witnessed the signing, which was also attended by Dr. Ayman Mokhtar, Regional President of Viatris for the Middle East, North Africa and Eurasia region, and Hamdan Mohammed Al Dhahmani, Chairman of the Board of Directors of Adcan Pharma.
A Second Agreement Links the Regulator to the Global Company
The Adcan Pharma deal sits alongside a memorandum of understanding signed between the Emirates Drug Establishment and Viatris, a global healthcare company. The memorandum was signed by Dr. Fatima Al Kaabi and Dr. Tamer El Salab, Group President for the Gulf and Levant regions at Viatris. It is a strategic move to boost investment opportunities and localise the pharmaceutical industry in the UAE, expanding partnerships with international companies and linking their expertise and advanced technologies with national capabilities.
According to the establishment, this is intended to raise the value added of the pharmaceutical sector, enhance its competitiveness, and consolidate the country's position as a regional and international centre for advanced pharmaceutical industries and life sciences.
What the MOU Covers
The areas of cooperation outlined in the memorandum include developing local manufacturing capabilities and strengthening the resilience of supply chains. It also covers developing Emirati talent through training initiatives, knowledge and experience exchange, and professional development opportunities, as well as support for pharmaceutical and health innovation.
The Regulator's Case for Investment
Dr. Fatima Al Kaabi said the UAE has established an integrated environment for investment in the pharmaceutical sector, combining advanced regulation, logistics infrastructure, research and development capabilities, and a strategic location. In her view, this allows global companies to build a long-term presence from within the country, expand toward regional markets, and benefit from the competitive advantages the UAE offers for business growth.
She added that the partnership with Viatris reflects the establishment's approach of consolidating a model for international partnerships built on transforming cooperation with global companies into long-term industrial and knowledge projects within the country.
The establishment, she said, is working to expand this model to attract quality investments and develop joint projects with national manufacturers, strengthening the UAE's position in global pharmaceutical value chains.
National Context for the Partnerships
The two agreements fall within the efforts of the Emirates Drug Establishment to develop the national pharmaceutical system according to the best international standards and practices. They aim to enhance integration between regulatory, industrial, and research roles in a way that supports drug security, sustains the availability of medical products, and raises the sector's contribution to the health and economic development of the country. The announcement was published by the establishment on its official portal on Wednesday, 11 November 2026.
Tracked in the database
Pharmaceutical Manufacturing Localisation Partnerships · Middle East
Pharmaceutical Manufacturing Localisation Partnerships
Middle East
Industrial
11 November 2026
3 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.